Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KLRS Kalaris Therapeutics	$2.27 -0.4%	$2.62	$2.14 ▼ $24.15	$42.64M	0.49	62,708 shs	75,076 shs
NLTX Neoleukin Therapeutics	$21.11 +9.8%	$20.44	$2.03 ▼ $14.36	$198.39M	1.11	50,104 shs	197,563 shs
OGI Organigram Global	$1.56 -2.5%	$1.42	$0.85 ▼ $2.08	$214.44M	1.45	833,761 shs	2.08 million shs
TRDA Entrada Therapeutics	$5.25 -1.3%	$6.67	$4.93 ▼ $21.79	$202.36M	-0.12	236,110 shs	228,068 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KLRS Kalaris Therapeutics	-8.43%	-13.64%	-12.64%	+227,999,900.00%	+227,999,900.00%
NLTX Neoleukin Therapeutics	-5.55%	-10.40%	-10.31%	+26.28%	-43.77%
OGI Organigram Global	+0.63%	+15.94%	+8.11%	+29.03%	-11.60%
TRDA Entrada Therapeutics	+3.10%	-10.59%	-21.76%	-34.48%	-66.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KLRS Kalaris Therapeutics	2.1377 of 5 stars	3.0	0.0	0.0	0.0	1.5	3.3	0.6
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	1.3244 of 5 stars	0.0	2.0	0.0	0.0	2.5	0.0	2.5
TRDA Entrada Therapeutics	2.7909 of 5 stars	3.6	3.0	0.0	0.0	1.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KLRS Kalaris Therapeutics	2.00	Hold	$3.00	32.16% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
OGI Organigram Global	0.00	N/A	N/A	N/A
TRDA Entrada Therapeutics	3.25	Buy	$25.67	388.89% Upside

Current Analyst Ratings Breakdown

Latest KLRS, NLTX, TRDA, and OGI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral	$3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$22.47 per share	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
OGI Organigram Global	$117.47M	1.78	N/A	N/A	$2.07 per share	0.75
TRDA Entrada Therapeutics	$79.48M	2.51	$1.62 per share	3.25	$9.98 per share	0.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KLRS Kalaris Therapeutics	-$58.77M	N/A	0.00	∞	N/A	N/A	-62.08%	-54.69%	N/A
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
OGI Organigram Global	-$33.39M	$0.10	15.60	N/A	N/A	8.05%	-5.93%	-4.39%	N/A
TRDA Entrada Therapeutics	$65.63M	-$1.78	N/A	N/A	N/A	-92.30%	-17.81%	-14.55%	N/A

Latest KLRS, NLTX, TRDA, and OGI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	KLRS Kalaris Therapeutics	-$0.51	-$0.61	-$0.10	-$0.61	N/A	N/A
8/13/2025	Q3 2025	OGI Organigram Global	-$0.01	-$0.03	-$0.02	-$0.03	$68.04 million	$50.49 million
8/6/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	-$1.04	-$0.18	-$1.04	$8.17 million	$1.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KLRS Kalaris Therapeutics	N/A	14.31	14.31
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
OGI Organigram Global	N/A	3.42	1.90
TRDA Entrada Therapeutics	N/A	18.64	18.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KLRS Kalaris Therapeutics	66.05%
NLTX Neoleukin Therapeutics	52.37%
OGI Organigram Global	34.63%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
KLRS Kalaris Therapeutics	74.99%
NLTX Neoleukin Therapeutics	1.58%
OGI Organigram Global	0.09%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KLRS Kalaris Therapeutics	110	18.70 million	4.68 million	N/A
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
OGI Organigram Global	860	134.03 million	133.91 million	Optionable
TRDA Entrada Therapeutics	110	38.04 million	34.95 million	Optionable

KLRS, NLTX, TRDA, and OGI Headlines

Recent News About These Companies

Roth Capital Has Pessimistic Outlook of TRDA Q3 Earnings

August 12 at 2:15 AM | americanbankingnews.com

What is William Blair's Forecast for TRDA Q3 Earnings?

August 12 at 2:15 AM | americanbankingnews.com

Entrada (TRDA) Q2 Revenue Drops 98%

August 11 at 8:47 PM | theglobeandmail.com

Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen

August 11 at 2:31 AM | americanbankingnews.com

HC Wainwright Issues Pessimistic Outlook for TRDA Earnings

August 11 at 2:04 AM | marketbeat.com

Roth Capital Issues Pessimistic Forecast for TRDA Earnings

August 11 at 2:03 AM | marketbeat.com

William Blair Issues Negative Forecast for TRDA Earnings

August 11 at 2:03 AM | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

August 9, 2025 | finance.yahoo.com

Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

August 6, 2025 | globenewswire.com

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?

July 31, 2025 | zacks.com

5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

July 13, 2025 | investing.com

Entrada therapeutics (TRDA) director Parmar sells $202k in stock

July 13, 2025 | investing.com

Ventures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 12, 2025 | insidertrades.com

Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

July 3, 2025 | investing.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 Shares

July 2, 2025 | insidertrades.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS, NLTX, TRDA, and OGI Company Descriptions

Kalaris Therapeutics NASDAQ:KLRS

$2.27 -0.01 (-0.44%)

As of 04:00 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Neoleukin Therapeutics NASDAQ:NLTX

$21.11 +1.89 (+9.83%)

As of 08/13/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Organigram Global NASDAQ:OGI

$1.56 -0.04 (-2.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.56 0.00 (0.00%)

As of 07:36 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

Entrada Therapeutics NASDAQ:TRDA

$5.25 -0.07 (-1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$5.24 -0.01 (-0.29%)

As of 07:40 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time